Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

Release Date: September 27, 2024

Expiration Date: September 27, 2025

Activity Overview

Community oncologists focused on treating patients with hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) need to navigate the multitude of advancements in surveillance, novel targeted therapies and immunotherapies, and treatment sequencing. Moreover, collaboration among surgical, radiation, and medical oncologists, as well as pathologists and nurses, is required for the multidisciplinary management of these patients to improve overall outcomes.

This online CME-certified educational activity provides an in-depth review of some of the key highlights from the 14th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2024) held July 18-20, 2024. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with HCC and BTC, putting recent clinical trial data into clinical context. Renowned experts provide insights into recent clinical data with a focus on advances in surveillance screenings, early-stage and advanced HCC, and BTC. The program is designed for those who did not view the live webcast and to help reinforce learnings for those who did.

Target Audience

This educational activity is directed toward physicians involved in the diagnosis, treatment, and management of liver cancer. Other health care professionals interested in the treatment of these malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

1. Explain the diagnostic criteria and critical molecular biomarkers to identify HCC and BTC and assist in treatment decision-making for patients with these tumors
2. Assess recent clinical evidence from studies evaluating current and emerging therapies for the management of patients with liver cancers including HCC and BTC
3. Integrate potentially practice-changing safety and efficacy evidence into individualized care plans for patients with HCC and BTC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.